European Study on Relapsed Retinoblastoma

A multi-center European clinical trial on relapsed retinoblastoma, a form of eye cancer in children.

Retinoblastoma is the most common malignant eye tumor in children. However, due to its rarity (3% of all pediatric cancers) as well as its complexity, its management requires close collaboration between ophthalmologists and oncologists.

As a result, treatment is concentrated in highly specialized centers.

Currently, treatments for retinoblastoma combine several options:

  • Firstly, focal intraocular treatments, such as: laser, thermochemotherapy or even cryocoagulation.
  • Secondly, systemic chemotherapy depending on the stage of the disease.

However, at the most advanced stages, these approaches are often ineffective. Therefore, more aggressive treatments are needed. These include radiotherapy and the removal of the diseased eye (enucleation). As a result, these heavy treatments leave significant after-effects. Indeed, the latter can be aesthetic and functional. In addition, these treatments may also increase the risk of developing secondary tumors due to radiation exposure.

The EuRbG2018 study on retinoblastoma aims to develop a personalized approach according to the type of relapse.

The main objectives of the study are, first of all, to reduce retinal toxicity, as well as the rate of relapse. It then aims to assess the toxicities and sequelae of the various short, medium and long term treatments. But also to assess the preservation of vision. Finally, it aims to determine the number of patients for whom enucleation could be avoided, 2 years after entering the study.


The main goal of this study is to improve treatments for children with relapsed retinoblastoma.

This multicenter phase II randomized study is coordinated by the CHUV Hospital in Lausanne. It is led by Prof. Maja Beck Popovic and her team from the Pediatric Oncology Unit at CHUV. Francis Munier of thel’Hôpital Ophtalmique Jules Gonin Jules Gonin Ophthalmic Hospital takes place for the ophthalmologic part of the trial. The study is planned on a European scale and will be carried out in the following pediatric oncology centers:

  • France, Institut Curie, Paris
  • Germany, University Hospital, Essen
  • Spain, Sant Joan de Déu Hospital, Barcelone
  • UK, Children’s Hospital of Birmingham, Birmingham
  • Italy, Ospedale Pediatrico Bambino Gesù, Roma
  • Italy, Azienda Ospedaliera Universitaria  Senese, Sienna

Ultimately, the results of this study will improve patient care. As well as the management and treatment of retinoblastoma, with more effectively and with less toxicity.

Zoé4life contributed CHF 50’000.- to this study. These funds were raised during the Gold in September 2020 campaign.

Sullens, may 2021

Poupée Zoé4life

Together we can make a difference

There are many ways to support us. Your commitment makes a difference for children with cancer and their families.

Act Now!